Li Geng, Li Zhen-Kun, Yang Hong-Jun, Zhan Zhi-Lai, Li Hong-Mei, Tang Shi-Huan
China-Japan Friendship Hospital Beijing 100029,China.
Beijing Big Brand League Technology Consulting Co.,Ltd. Beijing 100070,China.
Zhongguo Zhong Yao Za Zhi. 2021 Mar;46(5):1284-1292. doi: 10.19540/j.cnki.cjcmm.20201214.601.
It is the core of the development for Chinese patent medicine enterprises to cultivate large varieties of Chinese patent medicine, and the selection of potential "seed" products is the prerequisite for the cultivation strategy. By constructing the evaluation model from multiple dimensions of value and risk, we can conduct specialized evaluation of Chinese patent medicines to effectively, professionally and objectively select the "seed" products with large variety cultivation potential. In this paper, the establishment of a multidimensional evaluation system would be discussed from the aspects of drug naming and prescription composition, safety risk and supply guarantee of raw materials and medicinal materials, competition situation, access to policy catalogue, scientific and technological support, clinical evidence and recognition, systematical and standardized collection of information on product instructions, quality standards, policy catalogue, scientific and technological literature, market competition and clinical application of Chinese patent medicines. Through the objective evaluation index and the range of objective index, the multi-dimensional evaluation model on values and risks of Chinese patent medicine products was discussed. Based on this model, a batch of Chinese patent medicine products can be quickly and comprehensively analyzed, and quantitative comparison can be formed among different types and fields of products. According to the evaluation results of the model and the comprehensive evaluation of experts, high-quality "seed" products can be selec-ted, laying a solid foundation for the next step of large variety cultivation. With use of this model, we can further clarify the external competitive advantages and internal priority levels of each product, and provide support for enterprises to optimize product structure and improve product strategic layout.
培育中成药大品种是中成药企业发展的核心，而筛选有潜力的“种子”产品是培育策略的前提。通过构建价值与风险多维度评价模型，对中成药进行专项评价，能够有效、专业、客观地选出具有大品种培育潜力的“种子”产品。本文将从药品命名与处方组成、原料及药材的安全风险与供应保障、竞争态势、政策目录准入、科技支撑、临床证据与认可度、中成药产品说明书、质量标准、政策目录、科技文献、市场竞争及临床应用等方面的信息进行系统规范收集，探讨建立多维评价体系。通过客观评价指标及客观指标范围，论述中成药产品价值与风险的多维评价模型。基于该模型，能够快速全面地分析一批中成药产品，并在不同类型及领域的产品间形成量化比较。依据模型评价结果及专家综合评审，选出优质“种子”产品，为下一步大品种培育奠定坚实基础。运用该模型，能够进一步明确各产品的外部竞争优势及内部优先级，为企业优化产品结构、完善产品战略布局提供支撑。
